News
2022
-
-
Sysmex Receives Manufacturing and Marketing Approval for an Assay Kit to Identify Amyloid Beta (Aβ) Accumulation in the Brain, a Cause of Alzheimer's Disease, Using a Small Amount of Blood
– Measurement of Plasma Aβ Using Automated Immunoassay System HISCL™-5000/HISCL™-800 –
-
-
Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2023
-
-
Announcement Regarding Differences between Actual and Forecast Figures for the Six Months Ended September 30, 2022, and Revision of Full-Year Financial Forecasts (PDF：226KB)
-
-
Order of the Rising Sun to be Conferred to Hisashi Ietsugu
-
-
Cancer Lymph Node Metastasis Test System Using the OSNA™ Method Expanded to Cervical Cancer and Endometrial Cancer
- Acquisition of Partial Change to Approval for LYNOAMP™ CK19 in Japan -
-
-
Sysmex and JCR Pharmaceuticals Establish a Joint Venture in the Field of Regenerative Medicine and Cell Therapy
- Aiming for the Research & Development and Early Commercialization of Regenerative Medicine Products Using Stem Cells, etc. -
-
-
Sysmex Launches the UF-1500 Fully Automated Urine Particle Analyzer, a New Product for the Urine Sediment Testing Field
- Product Lineup Expanding for Small and Medium-sized Facilities -
-
-
Sysmex and TOHO PHARMACEUTICAL to Commence Dry Ice-free Supply of Quality Control Reagents for Clinical Chemistry Tests
- Realizing a Sustainable Cold Chain -
-
-
Sysmex Applies for a Partial Change for the OncoGuide™ NCC Oncopanel System as a Companion Diagnostic for the Treatment of Advanced Biliary Tract Cancer
- Contributing to the Development of Cancer Genomic Medicine through Partnerships with Pharmaceutical Companies -
-
-
Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2023
-
-
Pilot, Inc. Becomes Wholly-owned Sysmex Subsidiary Through the Acquisition of Outstanding Shares
- Reinforcing Software Design and Development Capabilities -
-
-
Announcement of Personnel Change (PDF：104KB)
-
-
Sysmex Launches Sample Transportation System Modules for XR™-Series of Automated Hematology Analyzer
- The world’s first automated quality control material measurements contribute to greater automation and efficiency in clinical testing - (PDF：422KB)
-
-
Sysmex Files for Manufacturing and Marketing Approval for Genetic Panel Testing System for Inherited Retinal Dystrophy (PDF：235KB)
-
-
Our Views and Policy Regarding Investment Unit Reduction (PDF：91KB)
-
-
Completion of Declaration of Conformity to the European IVD Directive for an Assay Kit that Measures Plasma Amyloid Beta (Aβ) Using the Automated Immunoassay System HISCL™-5000/HISCL™-800
- Testing Method that Assists in the Identification of Aβ Accumulation in the Brain - (PDF：236KB)
-
-
The Ajinomoto Foundation, Sysmex, and NEC initiate a cross-industry co-creation project to improve maternal and child health and nutrition in the Republic of Ghana
- Contributing to Universal “Nutrition” Health Coverage - (PDF：414KB)
-
-
Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2022
-
-
Sysmex Announces Changes from Financial Forecasts and Year-End Dividend for the Fiscal Year Ended March 31, 2022 (PDF：169KB)
-
-
Announcement of Executive Change (PDF：150KB)
-
-
Declaration of Achieving Carbon Neutrality by 2040
- Contributing to the Realization of a Sustainable Society Through Initiatives to Deal with Climate Change -
-
-
Astrego Diagnostics AB Becomes Wholly-owned Sysmex Subsidiary through the Acquisition of Outstanding Shares
- Commercialization of Rapid Antimicrobial Susceptibility Test to Reinforce Structure for Promoting AMR Countermeasures - (PDF：188KB)
-
-
Sysmex Employee to Receive “Medal with Purple Ribbon” in Spring 2022 Medal of Honor Awards (PDF：185KB)
-
-
Sponsorship of the Thematic Project “Amplification of Lives” of Expo 2025, Osaka, Kansai, Japan
-
-
Announcement of Organizational and Personnel Changes (PDF：117KB)
-
-
Sysmex Forms Capital and Business Tie-up with KAINOS Laboratories to Drive Growth in the Immunochemistry Field
- Deepening Alliance in Reagent Development/Production to Create a Win-Win Situation - (PDF：180KB)
-
-
Sysmex Establishes Subsidiary in Saudi Arabia
- Reinforcing Sales, Service, and Support Structures to Expand Business in a Growing Market - (PDF：162KB)
-
-
Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2022 (PDF：437KB)
-
-
Information about Termination of the Litigation against Sysmex Corporation and its Subsidiary (PDF：128KB)
-
-
Sysmex Files for Manufacturing and Marketing Approval for an Assay Kit that Assists in Identification of Amyloid Beta (Aβ) Accumulation in the Brain
- Measurement of Plasma Aβ Using Automated Immunoassay System HISCL™-5000/HISCL™-800 - (PDF：150KB)
